Martínez-Pías E, García-Azorín D, Trigo-López J, Sierra A, Guerrero-Peral A L
Hospital Clínico Universitario de Valladolid, Valladolid, España.
Instituto de Investigación Biomédica de Salamanca, Salamanca, España.
Rev Neurol. 2021 Feb 16;72(4):133-140. doi: 10.33588/rn.7204.2020583.
Despite representing a significant number of cases, patients with chronic migraine and daily headache are frequently excluded from large therapeutic clinical trials. These individuals have hardly been studied and could have specific properties. Development. A third of patients with chronic migraine may suffer from headaches every day, representing up to 1.7 - 3.3% of patients in a general neurology consultation. These patients are excluded from most studies, so little information is available. They may have a longer lasting migraine and different response to treatment. Patients with chronic migraine and daily headache may have complex pathophysiological mechanisms that favor the daily manifestation of migraine. The management of these patients is a therapeutic challenge, and OnabotulinumtoxinA may be useful.
Patients with chronic migraine and daily headache may have specific clinical and therapeutic characteristics. New studies could lead to differentiate it from chronic migraine.
尽管慢性偏头痛和每日头痛患者占相当数量，但他们在大型治疗性临床试验中常被排除。这些个体几乎未被研究过，可能具有特殊性质。发展情况。三分之一的慢性偏头痛患者可能每天都头痛，在普通神经科门诊患者中占比高达1.7% - 3.3%。这些患者被大多数研究排除在外，因此可用信息很少。他们的偏头痛可能持续时间更长，对治疗的反应也不同。慢性偏头痛和每日头痛患者可能具有复杂的病理生理机制，这有利于偏头痛的每日发作。对这些患者的管理是一项治疗挑战，而A型肉毒毒素可能有用。
慢性偏头痛和每日头痛患者可能具有特定的临床和治疗特征。新的研究可能有助于将其与慢性偏头痛区分开来。
